Streetbeat News

Equity Actions

ATRC

AtriCure (NASDAQ:ATRC) was analyzed by 6 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish or indifferent stances. The average 12-month price target is now $52.00, down from $59.00, with a high estimate of $60.00 and a low of $44.00. Analysts from Needham and JMP Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AtriCure specializes in surgical treatments for atrial fibrillation and related conditions, with a majority of revenue from the U.S. The company has shown strong revenue growth, net margin, ROE, and ROA, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

VZ

Seven analysts have recently provided diverse opinions on Verizon Communications (NYSE:VZ), with an average 12-month price target of $42.71, a slight decrease from the previous average. The ratings range from 'Outperform' to 'Equal-Weight', with price targets adjusted accordingly. Verizon's financials show a negative revenue trend, but strong net margin, ROE, and ROA, along with a healthy debt-to-equity ratio. Analysts' ratings are crucial for investors, reflecting expert opinions on stock performance and company prospects.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

MUSA

Murphy USA (NYSE:MUSA) received mixed analyst ratings in the latest quarter, with 1 bullish, 2 somewhat bullish, and 1 bearish rating. Analysts updated their price targets, with an average of $385.00, a high of $425.00, and a low of $280.00, reflecting an 11.38% increase from the previous average target. Corey Tarlowe of Jefferies and Ben Bienvenu of Stephens & Co. raised their targets, while Bonnie Herzog of Goldman Sachs also raised hers but maintains a sell rating. Murphy USA operates gasoline products and convenience stores, mostly adjacent to Walmart stores, and has shown strong financial health with a high ROE and ROA but faces revenue challenges.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

ILMN

Nine analysts have recently rated Illumina (NASDAQ:ILMN), with a mix of bullish to bearish sentiments. The average 12-month price target is now $168.11, a 13.79% decrease from the previous $195.00 target. Analysts from firms like RBC Capital, Guggenheim, and B of A Securities have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Illumina specializes in genetic analysis tools and services, with the majority of its revenue from sequencing. Despite positive revenue growth, the company's market capitalization, net margin, ROE, and ROA are below industry benchmarks, although it has a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

DINO

HF Sinclair Corporation has entered into a private transaction to repurchase 454,380 shares of its common stock from REH at a price of $55.02 per share, as disclosed in an 8-K filing.

Portfolio Pulse from Charles Gross

January 04, 2024 | 11:08 am

GS

Goldman Sachs Asset Management has closed its West Street Life Sciences I fund, raising $650 million, surpassing its target. The fund, which is the first in the firm's Life Sciences Investing strategy, will focus on growth-oriented private equity investments in early to mid-stage therapeutic companies, life sciences tools, and diagnostics companies. It has already committed approximately $90 million across five portfolio companies. Goldman Sachs Asset Management oversees more than $2.6 trillion in assets as of September 30, 2023. GS shares saw a slight increase of 0.32% in premarket trading.

Portfolio Pulse from Lekha Gupta

January 04, 2024 | 10:51 am

AMZN

TSLA

Jim Cramer, the host of CNBC's Mad Money, has advised investors to take profits on their Big Tech investments, highlighting the importance of profit-taking even when it's difficult to let go of shares from the 'Magnificent Seven', a group of top-performing tech companies. He mentioned that despite potential regrets of selling these stocks, the current market conditions might present a lower buy-in opportunity. Cramer specifically pointed out Amazon (AMZN) for its Prime Video service's revenue potential and Tesla (TSLA) for its future growth beyond electric vehicles.

Portfolio Pulse from Benzinga Neuro

January 04, 2024 | 7:46 am

CRM

META

NVDA

Mark Zuckerberg resumed selling Meta Platforms Inc. (META) shares after a two-year hiatus, offloading $428 million worth in the last two months of 2023. Zuckerberg sold shares every trading day from November 1 through year's end, totaling nearly 1.28 million shares. Meta's stock price rebounded in 2023, surging by 194% from a seven-year low. Marc Benioff of Salesforce Inc. (CRM) also sold over $475 million worth of shares in the second half of 2023. Despite the sales, these transactions represented a small portion of the tech moguls' wealth.

Portfolio Pulse from Benzinga Neuro

January 04, 2024 | 7:35 am

LBPH

Longboard Pharmaceuticals has priced an upsized public offering of 10 million common shares at $21 per share, raising $210 million in capital. This move could indicate the company's need for capital to fund its operations or growth initiatives.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:03 am

KROS

Keros Therapeutics has announced the pricing of an upsized public offering of 3.5 million common shares at $40 per share, aiming to raise $140 million.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:01 am